Cardiologist | Clinical Trialist | HSR. Passionate about prevention, value, learning health systems; keen runner; father of boys. RAH | UofA | VHI | DCRI
Australia
Joined March 2009
- Tweets309
- Following1.7K
- Followers902
- Likes4.3K
Looking forward to it @drhungo !!!
#ESCCongress2024 done 👏🏻 👏🏻
Gearing up for Brisbane GPCE ✈️ to talk Lipids & cardiovascular risk with good friend & colleague @ajnelson
Conference link/discount below 👇🏼
Code SPEAKER50ADV to get 50% off your Conference Pass. #GPCEBrisbane
invt.io/1txbv5ph0ub
Adam Nelson retweeted
#ESCCongress2024 done 👏🏻 👏🏻
Gearing up for Brisbane GPCE ✈️ to talk Lipids & cardiovascular risk with good friend & colleague @ajnelson
Conference link/discount below 👇🏼
Code SPEAKER50ADV to get 50% off your Conference Pass. #GPCEBrisbane
invt.io/1txbv5ph0ub
Adam Nelson retweeted
Results of the CAMERA-MRI II study LBCT #ESC2024: catheter ablation in AF and LVSD with LV fibrosis superior to medical therapy with respect to LVEF improvement, functional status, patient symptoms and reverse LA remodeling @ESCardioNews @drjohnm @peterkistler3 @drsunnyprabhu
Adam Nelson retweeted
Thrilled to present the results from the WITHDRAW-AF randomized clinical trial at #ESC2024 - low LVSD relapse rates in recovered AFCM following withdrawal of HF pharmacotherapy @BakerResearchAu @UniMelb @AlfHeartCentre @escardio @drjohnm – at London, England
Adam Nelson retweeted
Loss of kidney function accelerates dramatically after HF, while atherosclerotic & HF risk increases 3-4 fold after CKD progression
Highlighting epidemiological & therapeutic synergies between CKD & CV disease
Cardio-kidney-metabolic #simpub for #ESCCongress in @JACCJournals
New analysis from CANVAS and CREDENCE trials reveals a bidirectional relationship between CV events and #CKD progression in type 2 #diabetes bit.ly/3X747wK
#ESCCongress #JACC #T2D #MACE @brendonneuen @mvaduganathan
Adam Nelson retweeted
Patients with HFrEF have ⬆️ incident cancer but undergo ⬇️ cancer screening than the general population (despite expressing interest).
Should we include cancer screening in HFrEF programs?
japscjournal.com/articles/ca…
#cardiooncology #reversecardiooncology
@MonashVHI
Fantastic work by @cardiopharmnerd - discharge pathways post PCI and CABG look different but use of secondary prevention medications should be similar… plenty of opportunities to improve adoption of evidence based therapies. doi.org/10.1016/j.hlc.2024.0…
Absolutely stoked to be featured in the Limbic yesterday, check out the story behind revascularization and secondary prevention medication use on Victoria:
Preventive meds after MI depend on revascularisation strategy: thelimbic.com/cardiology/pre…
Thanks for the opportunity @ProfSNicholls & @lamcardio ...
Despite housing 60% of the global burden of CVD, our earlier work has shown that < 10% of participants enrolled in seminal cardiometabolic studies are from APAC.
Huge opportunities
@the_apcmc
jacc.org/doi/abs/10.1016/j.j…
This Post is from an account that no longer exists. Learn more
Adam Nelson retweeted
REGISTER: thelimbic.com/nephrology/car…
A MDT panel presents the latest updates on the use of disease-modifying treatments in cardio-renal metabolic disease and discusses models of care for improved patient outcomes.
@brendonneuen @KrishRathika @ajnelson @DrSarahGlastras
@ANZSN
Adam Nelson retweeted
Many practical challenges affect ASCVD prevention in patients with cancer treated immunotherapy. Huge scope for opportunistic screening and implementation research in #CardioOncology @ProfSNicholls @profevasegelov @ajnelson @MonashVHI @ESC_Journals
doi.org/10.1093/eurjpc/zwae2…
Adam Nelson retweeted
Happy to inform our “remote follow-up in #PragmaticTrials” at #ACC has #SimPub to @JCardFail. Thanks for the team and mentorship from @_adevore
@DukeCardFellows
@DCRINews
@robmentz
@gcfmd
@JavedButler1
@kofi_larry
@DukeHFDoc
@FudimMarat
@ajnelson
@texhern
bit.ly/49uzN3e
Great to have @SJGreene_md all the way from @DCRINews here in Adelaide @thecsanz reminding us of the importance of simultaneous commencement & rapid titration of HFrEF therapies. Incredible body of work highlighting gaps and importantly a path forward! @lamcardio
Great to have @WongChrisX back in town kicking off @SAHMRI_Heart emerging leaders symposium. Translational data linking dietary factors with propensity for arrhythmia. @UniofAdelaide @Elliott_AD @PrashSanders @ChrisBursill
Adam Nelson retweeted
Excellent summary of the renal benefits SGLT2 inhibitors by @SantosGallegoMD at #ADA2023
@JavedButler1 @hvanspall @ajnelson @MWilkinsonMD @MountSinaiHeart
Adam Nelson retweeted
Patients receiving immune checkpoint inhibitors for cancer routinely have their BP checked when they attend for treatment.
Could we be repurposing this for hypertension screening?
nature.com/articles/s41371-0…
@ProfSNicholls @ajnelson @profevasegelov @MonashVHI #CardioOncology
Thanks @JAMACardio for publishing our work which simulated the impact of volume and performance-based thresholds on TAVI outcomes and access in the @ACCinTouch NCDR TVT registry.
Simulated outcome-thresholds could potentially improve TAVI outcomes to a greater extent than volume thresholds, at the cost of reduced geographic access to care. ja.ma/40LT9O2
Our study has limitations. We used simulations and adjusted models including a number of assumptions such as constant site-level outcomes despite increased modelled capacity. Notwithstanding these, we hope our work stimulates discussion in the evidence-based policy space.
Thanks to Sreek Vemulapalli for his leadership, and to Sean O'Brien and Dianne Gallup for their tireless statistical support @DCRINews, as well as a village of supportive coauthors, some of whom are on twitter...@djc795 @ajaykirtane @NimeshDesaiMD @ericpetersonMD